{
  "docId": "019de077-2202-715b-adea-57c1f9ae9ce5",
  "docSlug": "719db50244a96da2bbf79cc8f7d91684",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 26,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "Data presented at EASL 2024. Includes pie charts comparing Group A and Group B across three metrics: time off NA therapy, HBV DNA levels, and HBsAg levels.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2202-715b-adea-57c1f9ae9ce5/17",
  "deckHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5",
  "deckJsonHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5.json",
  "deckAnchorHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.15,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Pie charts showing Time off NA therapy, HBV DNA <LLOQ, and HBsAg levels for Group A and Group B",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70e3ebc3-7239-4c54-a06b-dfc73f5a446d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.15,
        "y": 0.9
      },
      "kind": "legend",
      "text": "1-3 mo, 4-6 mo, >6 mo, <LLOQ, >=LLOQ, <=LLOQ, 0.05-<10, 10-<100, >=100",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de544d1a-e9ef-463d-b947-98dfbc7e9e50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.18
      },
      "kind": "list",
      "text": "Imdusiran and VTP-300 was generally safe and well-tolerated; No SAEs, Grade 3 or 4 adverse events; Most common treatment-related AEs were injection site-related (Grade 1 or 2)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b24d1ef-201d-4b8a-82ed-e586229cccd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "list",
      "text": "84% of patients in Group A/VTP-300 met NA discontinuation criteria and stopped treatment after W48; More Group A/VTP-300 subjects (50%) have maintained HBV DNA <LLOQ off NA therapy than placebo subjects (37.5%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce2fc9ce-c84a-4d6e-9f7f-c9dfaae6cdfb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "IM-PROVE II: More patients Treated with Imdusiran and VTP-300 stopped NA treatment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10aead59-aba6-4eb9-afca-f440c6a1734e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "80de7daa-7de3-4e19-8b40-509460dcdb86",
      "evidence": "The slide includes a chart/pie, which suggests the use of a chart to present information.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 13,
      "beatId": "a03442fb-e554-4013-a27a-a70f868887ac",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document showcases positive clinical trial results for Imdusiran and AB-101.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}